The content on this site is intended for healthcare professionals only
Dr Eric Bouffet presents study findings, where he found two targeted therapies, dabrafenib (taflinar) plus trametinib (mekinst), significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in paediatric patients with BRAF V600 mutation-positive low-grade gliomas.
The next steps for this study are that researchers hope to learn more about the optimal duration of treatment.
Also, the researchers hope to determine if this treatment fits into the World Health Organisation (WHO) global initiative for childhood cancer.
Read the news story here
Watch Dr Hudson comment on the study here
Watch Dr Bouffet's interview on the study here
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL
